Cayman
Showing 27901–28050 of 45550 results
-
Lonidamine, originally identified as a potent antispermatogenic agent, inhibits glycolysis though the inactivation of mitochondria-bound hexokinase. It can decrease oxygen consumption as well as aerobic and anaerobic glycolysis in Ehrlich ascites tumor cells with IC50 values of 90 and 45 μM, respectively.{23379} A role for lonidamine as a therapeutic for mitochondrial dysfunction has been explored in various disorders, including cancer, neurodegenerative and neuromuscular diseases, obesity, and diabetes.{23378,23377,23376}
Brand:CaymanSKU:- Lonidamine, originally identified as a potent antispermatogenic agent, inhibits glycolysis though the inactivation of mitochondria-bound hexokinase. It can decrease oxygen consumption as well as aerobic and anaerobic glycolysis in Ehrlich ascites tumor cells with IC50 values of 90 and 45 μM, respectively.{23379} A role for lonidamine as a therapeutic for mitochondrial dysfunction has been explored in various disorders, including cancer, neurodegenerative and neuromuscular diseases, obesity, and diabetes.{23378,23377,23376}
Brand:CaymanSKU:- Lonidamine, originally identified as a potent antispermatogenic agent, inhibits glycolysis though the inactivation of mitochondria-bound hexokinase. It can decrease oxygen consumption as well as aerobic and anaerobic glycolysis in Ehrlich ascites tumor cells with IC50 values of 90 and 45 μM, respectively.{23379} A role for lonidamine as a therapeutic for mitochondrial dysfunction has been explored in various disorders, including cancer, neurodegenerative and neuromuscular diseases, obesity, and diabetes.{23378,23377,23376}
Brand:CaymanSKU:- Lonidamine, originally identified as a potent antispermatogenic agent, inhibits glycolysis though the inactivation of mitochondria-bound hexokinase. It can decrease oxygen consumption as well as aerobic and anaerobic glycolysis in Ehrlich ascites tumor cells with IC50 values of 90 and 45 μM, respectively.{23379} A role for lonidamine as a therapeutic for mitochondrial dysfunction has been explored in various disorders, including cancer, neurodegenerative and neuromuscular diseases, obesity, and diabetes.{23378,23377,23376}
Brand:CaymanSKU:-
Loperamide is an opiate which potently and selectively activates μ opioid receptors (Ki = 0.16 nM) exclusively in the periphery. Loperamide is an opiate which potently and selectively activates μ opioid receptors (Ki = 0.16 nM) exclusively in the periphery.{23761,23758} It is a much weaker agonist of the δ opioid receptor (Ki = 50 nM).{23761} Through its actions in the gut wall, loperamide has antidiarrheal action by increasing transit time and by altering intestinal transport of water and electrolytes.{23758,23756} It also blocks voltage-sensitive sodium channels (IC50 = 270 nM) and high voltage-activated calcium channels (IC50 = 900 nM), presumably through an inhibitory effect on calmodulin.{23759,23760,23758} Loperamide is comparable to morphine in blocking peripheral pain in rats.{23757}
Brand:CaymanSKU:- Loperamide is an opiate which potently and selectively activates μ opioid receptors (Ki = 0.16 nM) exclusively in the periphery. Loperamide is an opiate which potently and selectively activates μ opioid receptors (Ki = 0.16 nM) exclusively in the periphery.{23761,23758} It is a much weaker agonist of the δ opioid receptor (Ki = 50 nM).{23761} Through its actions in the gut wall, loperamide has antidiarrheal action by increasing transit time and by altering intestinal transport of water and electrolytes.{23758,23756} It also blocks voltage-sensitive sodium channels (IC50 = 270 nM) and high voltage-activated calcium channels (IC50 = 900 nM), presumably through an inhibitory effect on calmodulin.{23759,23760,23758} Loperamide is comparable to morphine in blocking peripheral pain in rats.{23757}
Brand:CaymanSKU:- Loperamide is an opiate which potently and selectively activates μ opioid receptors (Ki = 0.16 nM) exclusively in the periphery. Loperamide is an opiate which potently and selectively activates μ opioid receptors (Ki = 0.16 nM) exclusively in the periphery.{23761,23758} It is a much weaker agonist of the δ opioid receptor (Ki = 50 nM).{23761} Through its actions in the gut wall, loperamide has antidiarrheal action by increasing transit time and by altering intestinal transport of water and electrolytes.{23758,23756} It also blocks voltage-sensitive sodium channels (IC50 = 270 nM) and high voltage-activated calcium channels (IC50 = 900 nM), presumably through an inhibitory effect on calmodulin.{23759,23760,23758} Loperamide is comparable to morphine in blocking peripheral pain in rats.{23757}
Brand:CaymanSKU:- Loperamide is an opiate which potently and selectively activates μ opioid receptors (Ki = 0.16 nM) exclusively in the periphery. Loperamide is an opiate which potently and selectively activates μ opioid receptors (Ki = 0.16 nM) exclusively in the periphery.{23761,23758} It is a much weaker agonist of the δ opioid receptor (Ki = 50 nM).{23761} Through its actions in the gut wall, loperamide has antidiarrheal action by increasing transit time and by altering intestinal transport of water and electrolytes.{23758,23756} It also blocks voltage-sensitive sodium channels (IC50 = 270 nM) and high voltage-activated calcium channels (IC50 = 900 nM), presumably through an inhibitory effect on calmodulin.{23759,23760,23758} Loperamide is comparable to morphine in blocking peripheral pain in rats.{23757}
Brand:CaymanSKU:-
Lopinavir is a potent HIV-1 protease inhibitor (Ki = 1.3 pM for wild-type enzyme).{24199} It inhibits the replication of clinical isolates of HIV-1 (EC50s = 5-52 nM). Lopinavir reduces the infectious virus yield and viral RNA copy numbers in the culture supernatant of Vero E6 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; EC50s = 26.63 and 26.10 µM, respectively).{53655} It reduces lung and kidney viral load, bronchointerstitial pneumonia, and pulmonary inflammatory cell infiltration in a marmoset model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection when administered in combination with ritonavir (Item No. 13872).{53656}
Brand:CaymanSKU:- Lopinavir is a potent HIV-1 protease inhibitor (Ki = 1.3 pM for wild-type enzyme).{24199} It inhibits the replication of clinical isolates of HIV-1 (EC50s = 5-52 nM). Lopinavir reduces the infectious virus yield and viral RNA copy numbers in the culture supernatant of Vero E6 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; EC50s = 26.63 and 26.10 µM, respectively).{53655} It reduces lung and kidney viral load, bronchointerstitial pneumonia, and pulmonary inflammatory cell infiltration in a marmoset model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection when administered in combination with ritonavir (Item No. 13872).{53656}
Brand:CaymanSKU:- Lopinavir is a potent HIV-1 protease inhibitor (Ki = 1.3 pM for wild-type enzyme).{24199} It inhibits the replication of clinical isolates of HIV-1 (EC50s = 5-52 nM). Lopinavir reduces the infectious virus yield and viral RNA copy numbers in the culture supernatant of Vero E6 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; EC50s = 26.63 and 26.10 µM, respectively).{53655} It reduces lung and kidney viral load, bronchointerstitial pneumonia, and pulmonary inflammatory cell infiltration in a marmoset model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection when administered in combination with ritonavir (Item No. 13872).{53656}
Brand:CaymanSKU:- Lopinavir is a potent HIV-1 protease inhibitor (Ki = 1.3 pM for wild-type enzyme).{24199} It inhibits the replication of clinical isolates of HIV-1 (EC50s = 5-52 nM). Lopinavir reduces the infectious virus yield and viral RNA copy numbers in the culture supernatant of Vero E6 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; EC50s = 26.63 and 26.10 µM, respectively).{53655} It reduces lung and kidney viral load, bronchointerstitial pneumonia, and pulmonary inflammatory cell infiltration in a marmoset model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection when administered in combination with ritonavir (Item No. 13872).{53656}
Brand:CaymanSKU:-
Lopinavir-d8 is intended for use as an internal standard for the quantification of lopinavir (Item No. 13854) by GC- or LC-MS. Lopinavir is a potent HIV-1 protease inhibitor (Ki = 1.3 pM for wild-type enzyme).{24199} It inhibits the replication of clinical isolates of HIV-1 (EC50s = 5-52 nM). Lopinavir reduces the infectious virus yield and viral RNA copy numbers in the culture supernatant of Vero E6 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; EC50s = 26.63 and 26.10 µM, respectively).{53655} It reduces lung and kidney viral load, bronchointerstitial pneumonia, and pulmonary inflammatory cell infiltration in a marmoset model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection when administered in combination with ritonavir (Item No. 13872).{53656}
Brand:CaymanSKU:25284 - 1 mgAvailable on backorder
Loratadine is a non-sedating antihistamine that acts as a selective inverse agonist of peripheral histamine H1 receptors (Ki = 35 nM).{25629,22788,25628} It has been shown to inhibit the release of leukotriene C4 (IC50 = 8 µM) and histamine (IC50 = 11 µM) from rodent mast cells and to inhibit allergic bronchospasm in guinea pigs with an ED50 value of 0.40 mg/kg.{25627} Formulations containing loratadine have been used in the treatment of allergic rhinitis and chronic idiopathic urticaria.
Brand:CaymanSKU:- Loratadine is a non-sedating antihistamine that acts as a selective inverse agonist of peripheral histamine H1 receptors (Ki = 35 nM).{25629,22788,25628} It has been shown to inhibit the release of leukotriene C4 (IC50 = 8 µM) and histamine (IC50 = 11 µM) from rodent mast cells and to inhibit allergic bronchospasm in guinea pigs with an ED50 value of 0.40 mg/kg.{25627} Formulations containing loratadine have been used in the treatment of allergic rhinitis and chronic idiopathic urticaria.
Brand:CaymanSKU:- Loratadine is a non-sedating antihistamine that acts as a selective inverse agonist of peripheral histamine H1 receptors (Ki = 35 nM).{25629,22788,25628} It has been shown to inhibit the release of leukotriene C4 (IC50 = 8 µM) and histamine (IC50 = 11 µM) from rodent mast cells and to inhibit allergic bronchospasm in guinea pigs with an ED50 value of 0.40 mg/kg.{25627} Formulations containing loratadine have been used in the treatment of allergic rhinitis and chronic idiopathic urticaria.
Brand:CaymanSKU:- Loratadine is a non-sedating antihistamine that acts as a selective inverse agonist of peripheral histamine H1 receptors (Ki = 35 nM).{25629,22788,25628} It has been shown to inhibit the release of leukotriene C4 (IC50 = 8 µM) and histamine (IC50 = 11 µM) from rodent mast cells and to inhibit allergic bronchospasm in guinea pigs with an ED50 value of 0.40 mg/kg.{25627} Formulations containing loratadine have been used in the treatment of allergic rhinitis and chronic idiopathic urticaria.
Brand:CaymanSKU:-
Loratadine-d5 is intended for use as an internal standard for the quantification of loratadine (Item No. 15625) by GC- or LC-MS. Loratadine is a non-sedating antihistamine that acts as a selective inverse agonist of peripheral histamine H1 receptors (Ki = 35 nM).{25629,22788,25628} It has been shown to inhibit the release of leukotriene C4 (IC50 = 8 µM) and histamine (IC50 = 11 µM) from rodent mast cells and to inhibit allergic bronchospasm in guinea pigs with an ED50 value of 0.40 mg/kg.{25627} Formulations containing loratadine have been used in the treatment of allergic rhinitis and chronic idiopathic urticaria.
Brand:CaymanSKU:25040 - 1 mgAvailable on backorder
Loratadine-d5 is intended for use as an internal standard for the quantification of loratadine (Item No. 15625) by GC- or LC-MS. Loratadine is a non-sedating antihistamine that acts as a selective inverse agonist of peripheral histamine H1 receptors (Ki = 35 nM).{25629,22788,25628} It has been shown to inhibit the release of leukotriene C4 (IC50 = 8 µM) and histamine (IC50 = 11 µM) from rodent mast cells and to inhibit allergic bronchospasm in guinea pigs with an ED50 value of 0.40 mg/kg.{25627} Formulations containing loratadine have been used in the treatment of allergic rhinitis and chronic idiopathic urticaria.
Brand:CaymanSKU:25040 - 5 mgAvailable on backorder
Loratadine-d5 is intended for use as an internal standard for the quantification of loratadine (Item No. 15625) by GC- or LC-MS. Loratadine is a non-sedating antihistamine that acts as a selective inverse agonist of peripheral histamine H1 receptors (Ki = 35 nM).{25629,22788,25628} It has been shown to inhibit the release of leukotriene C4 (IC50 = 8 µM) and histamine (IC50 = 11 µM) from rodent mast cells and to inhibit allergic bronchospasm in guinea pigs with an ED50 value of 0.40 mg/kg.{25627} Formulations containing loratadine have been used in the treatment of allergic rhinitis and chronic idiopathic urticaria.
Brand:CaymanSKU:25040 - 500 µgAvailable on backorder
Lorediplon is a ligand for α1 subunit-containing GABAA receptors.{40790} In vivo, lorediplon inhibits spontaneous motor activity and increases duration of sleep in mice (ED50s = 0.13 and 1.2 mg/kg, respectively). It selectively inhibits spontaneous motor activity, which is driven by α1 subunit-containing GABAA receptors, over modification of muscular tone in mice, an α2 subunit-containing GABAA receptor-stimulated activity.{40791} Lorediplon (0.13 and 1.2 mg/kg) also decreases latency to slow wave sleep (SWS) and paradoxical sleep (PS) in mice.{40792} Formulations containing lorediplon have been used in the treatment of insomnia.
Brand:CaymanSKU:23868 - 10 mgAvailable on backorder
Lorediplon is a ligand for α1 subunit-containing GABAA receptors.{40790} In vivo, lorediplon inhibits spontaneous motor activity and increases duration of sleep in mice (ED50s = 0.13 and 1.2 mg/kg, respectively). It selectively inhibits spontaneous motor activity, which is driven by α1 subunit-containing GABAA receptors, over modification of muscular tone in mice, an α2 subunit-containing GABAA receptor-stimulated activity.{40791} Lorediplon (0.13 and 1.2 mg/kg) also decreases latency to slow wave sleep (SWS) and paradoxical sleep (PS) in mice.{40792} Formulations containing lorediplon have been used in the treatment of insomnia.
Brand:CaymanSKU:23868 - 25 mgAvailable on backorder
Lorediplon is a ligand for α1 subunit-containing GABAA receptors.{40790} In vivo, lorediplon inhibits spontaneous motor activity and increases duration of sleep in mice (ED50s = 0.13 and 1.2 mg/kg, respectively). It selectively inhibits spontaneous motor activity, which is driven by α1 subunit-containing GABAA receptors, over modification of muscular tone in mice, an α2 subunit-containing GABAA receptor-stimulated activity.{40791} Lorediplon (0.13 and 1.2 mg/kg) also decreases latency to slow wave sleep (SWS) and paradoxical sleep (PS) in mice.{40792} Formulations containing lorediplon have been used in the treatment of insomnia.
Brand:CaymanSKU:23868 - 5 mgAvailable on backorder
Lorediplon is a ligand for α1 subunit-containing GABAA receptors.{40790} In vivo, lorediplon inhibits spontaneous motor activity and increases duration of sleep in mice (ED50s = 0.13 and 1.2 mg/kg, respectively). It selectively inhibits spontaneous motor activity, which is driven by α1 subunit-containing GABAA receptors, over modification of muscular tone in mice, an α2 subunit-containing GABAA receptor-stimulated activity.{40791} Lorediplon (0.13 and 1.2 mg/kg) also decreases latency to slow wave sleep (SWS) and paradoxical sleep (PS) in mice.{40792} Formulations containing lorediplon have been used in the treatment of insomnia.
Brand:CaymanSKU:23868 - 50 mgAvailable on backorder
Cholecystokinin (CCK) is a peptide hormone that, through specific receptors, induces pancreatic growth and enzyme secretion, smooth muscle contraction in the gall bladder and stomach, and modulates feeding and behavior.{16813,16024,16665} Lorglumide is a nonpeptidic antagonist of the CCK A receptor (CCK1; IC50 = 50 nM) that is 60-fold less effective at the CCK B receptor (CCK2; IC50 = 3 µM).{28711} It blocks CCK-mediated gut muscle contraction, pancreatic growth, and pancreatic secretion.{28708,28712,28713} Lorglumide is commonly used to study the roles of CCK1 in tissues and in animals.{28709,28710}
Brand:CaymanSKU:-Available on backorder
Cholecystokinin (CCK) is a peptide hormone that, through specific receptors, induces pancreatic growth and enzyme secretion, smooth muscle contraction in the gall bladder and stomach, and modulates feeding and behavior.{16813,16024,16665} Lorglumide is a nonpeptidic antagonist of the CCK A receptor (CCK1; IC50 = 50 nM) that is 60-fold less effective at the CCK B receptor (CCK2; IC50 = 3 µM).{28711} It blocks CCK-mediated gut muscle contraction, pancreatic growth, and pancreatic secretion.{28708,28712,28713} Lorglumide is commonly used to study the roles of CCK1 in tissues and in animals.{28709,28710}
Brand:CaymanSKU:-Available on backorder
Cholecystokinin (CCK) is a peptide hormone that, through specific receptors, induces pancreatic growth and enzyme secretion, smooth muscle contraction in the gall bladder and stomach, and modulates feeding and behavior.{16813,16024,16665} Lorglumide is a nonpeptidic antagonist of the CCK A receptor (CCK1; IC50 = 50 nM) that is 60-fold less effective at the CCK B receptor (CCK2; IC50 = 3 µM).{28711} It blocks CCK-mediated gut muscle contraction, pancreatic growth, and pancreatic secretion.{28708,28712,28713} Lorglumide is commonly used to study the roles of CCK1 in tissues and in animals.{28709,28710}
Brand:CaymanSKU:-Available on backorder
Cholecystokinin (CCK) is a peptide hormone that, through specific receptors, induces pancreatic growth and enzyme secretion, smooth muscle contraction in the gall bladder and stomach, and modulates feeding and behavior.{16813,16024,16665} Lorglumide is a nonpeptidic antagonist of the CCK A receptor (CCK1; IC50 = 50 nM) that is 60-fold less effective at the CCK B receptor (CCK2; IC50 = 3 µM).{28711} It blocks CCK-mediated gut muscle contraction, pancreatic growth, and pancreatic secretion.{28708,28712,28713} Lorglumide is commonly used to study the roles of CCK1 in tissues and in animals.{28709,28710}
Brand:CaymanSKU:-Available on backorder
Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that potently inhibits both COX-1 and COX-2 (IC50s = 5 and 8 nM, respectively).{7909} It is used, in a variety of different formulations, as an analgesic.{31672,31673,31674}
Brand:CaymanSKU:70220 - 100 mgAvailable on backorder
Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that potently inhibits both COX-1 and COX-2 (IC50s = 5 and 8 nM, respectively).{7909} It is used, in a variety of different formulations, as an analgesic.{31672,31673,31674}
Brand:CaymanSKU:70220 - 250 mgAvailable on backorder
Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that potently inhibits both COX-1 and COX-2 (IC50s = 5 and 8 nM, respectively).{7909} It is used, in a variety of different formulations, as an analgesic.{31672,31673,31674}
Brand:CaymanSKU:70220 - 50 mgAvailable on backorder
Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that potently inhibits both COX-1 and COX-2 (IC50s = 5 and 8 nM, respectively).{7909} It is used, in a variety of different formulations, as an analgesic.{31672,31673,31674}
Brand:CaymanSKU:70220 - 500 mgAvailable on backorder
Angiotensin II is a hormone that plays an important role in regulating blood pressure.{9986} Elevated levels of angiotensin II are implicated in inducing and maintaining hypertension, and also in the development of atherosclerosis. Both of these effects are mediated by the angiotensin II type 1 (AT1) receptor.{12999} Losartan is an AT1 receptor antagonist with a Ki value of 5-20 nM.{12997} It has an attenuating effect on vein graft atherosclerosis in rabbits and effectively reduces arterial blood pressure in rats.{12998,13089} In humans, losartan controls hypertension while protecting renal function.{12996}
Brand:CaymanSKU:10006594 - 10 mgAvailable on backorder
Angiotensin II is a hormone that plays an important role in regulating blood pressure.{9986} Elevated levels of angiotensin II are implicated in inducing and maintaining hypertension, and also in the development of atherosclerosis. Both of these effects are mediated by the angiotensin II type 1 (AT1) receptor.{12999} Losartan is an AT1 receptor antagonist with a Ki value of 5-20 nM.{12997} It has an attenuating effect on vein graft atherosclerosis in rabbits and effectively reduces arterial blood pressure in rats.{12998,13089} In humans, losartan controls hypertension while protecting renal function.{12996}
Brand:CaymanSKU:10006594 - 100 mgAvailable on backorder
Angiotensin II is a hormone that plays an important role in regulating blood pressure.{9986} Elevated levels of angiotensin II are implicated in inducing and maintaining hypertension, and also in the development of atherosclerosis. Both of these effects are mediated by the angiotensin II type 1 (AT1) receptor.{12999} Losartan is an AT1 receptor antagonist with a Ki value of 5-20 nM.{12997} It has an attenuating effect on vein graft atherosclerosis in rabbits and effectively reduces arterial blood pressure in rats.{12998,13089} In humans, losartan controls hypertension while protecting renal function.{12996}
Brand:CaymanSKU:10006594 - 50 mgAvailable on backorder
Angiotensin II is a hormone that plays an important role in regulating blood pressure.{9986} Elevated levels of angiotensin II are implicated in inducing and maintaining hypertension, and also in the development of atherosclerosis. Both of these effects are mediated by the angiotensin II type 1 (AT1) receptor.{12999} Losartan is an AT1 receptor antagonist with a Ki value of 5-20 nM.{12997} It has an attenuating effect on vein graft atherosclerosis in rabbits and effectively reduces arterial blood pressure in rats.{12998,13089} In humans, losartan controls hypertension while protecting renal function.{12996}
Brand:CaymanSKU:10006594 - 500 mgAvailable on backorder
Losartan carboxaldehyde is an intermediate aldehyde metabolite of the angiotensin II type 1 receptor antagonist, losartan (Item No. 10006594). It does not block angiotensin receptors, but instead inhibits endothelial cyclooxygenase (COX)-2 expression, thereby exerting anti-inflammatory actions.{30560} At 1 µM in vitro, losartan carboxaldehyde has also been shown to block the upregulation of intercellular adhesion molecule (ICAM)-1 mRNA and COX-dependent generation of thromboxane A2 and prostaglandin F2α (Item No. 16010).{30560} Losartan carboxaldehyde can also act as a partial agonist (EC50 = 17.1 µM) of the insulin-sensitizing peroxisome proliferator-activated receptor γ in vitro.{30561,30559}
Brand:CaymanSKU:-Available on backorder
Losartan carboxaldehyde is an intermediate aldehyde metabolite of the angiotensin II type 1 receptor antagonist, losartan (Item No. 10006594). It does not block angiotensin receptors, but instead inhibits endothelial cyclooxygenase (COX)-2 expression, thereby exerting anti-inflammatory actions.{30560} At 1 µM in vitro, losartan carboxaldehyde has also been shown to block the upregulation of intercellular adhesion molecule (ICAM)-1 mRNA and COX-dependent generation of thromboxane A2 and prostaglandin F2α (Item No. 16010).{30560} Losartan carboxaldehyde can also act as a partial agonist (EC50 = 17.1 µM) of the insulin-sensitizing peroxisome proliferator-activated receptor γ in vitro.{30561,30559}
Brand:CaymanSKU:-Available on backorder
Losartan carboxaldehyde is an intermediate aldehyde metabolite of the angiotensin II type 1 receptor antagonist, losartan (Item No. 10006594). It does not block angiotensin receptors, but instead inhibits endothelial cyclooxygenase (COX)-2 expression, thereby exerting anti-inflammatory actions.{30560} At 1 µM in vitro, losartan carboxaldehyde has also been shown to block the upregulation of intercellular adhesion molecule (ICAM)-1 mRNA and COX-dependent generation of thromboxane A2 and prostaglandin F2α (Item No. 16010).{30560} Losartan carboxaldehyde can also act as a partial agonist (EC50 = 17.1 µM) of the insulin-sensitizing peroxisome proliferator-activated receptor γ in vitro.{30561,30559}
Brand:CaymanSKU:-Available on backorder
Losartan carboxylic acid is a physiologically active metabolite of losartan, produced by cytochrome P450 isoforms in the liver.{28030} Like the parent compound, losartan carboxylic acid is a potent AT1 antagonist (Kis = 0.57 and 0.67 nM for rat and human forms, respectively), producing a depressor response and vasodilatation.{28032,28031,21001} When administered intravenously, losartan carboxylic acid is more potent and has a longer duration of action than losartan.{21001} However, the metabolite has very low oral bioavailability.{21001} Losartan, but not its metabolite, inhibits platelet aggregation in vitro.{20999}
Brand:CaymanSKU:- Losartan carboxylic acid is a physiologically active metabolite of losartan, produced by cytochrome P450 isoforms in the liver.{28030} Like the parent compound, losartan carboxylic acid is a potent AT1 antagonist (Kis = 0.57 and 0.67 nM for rat and human forms, respectively), producing a depressor response and vasodilatation.{28032,28031,21001} When administered intravenously, losartan carboxylic acid is more potent and has a longer duration of action than losartan.{21001} However, the metabolite has very low oral bioavailability.{21001} Losartan, but not its metabolite, inhibits platelet aggregation in vitro.{20999}
Brand:CaymanSKU:- Losartan carboxylic acid is a physiologically active metabolite of losartan, produced by cytochrome P450 isoforms in the liver.{28030} Like the parent compound, losartan carboxylic acid is a potent AT1 antagonist (Kis = 0.57 and 0.67 nM for rat and human forms, respectively), producing a depressor response and vasodilatation.{28032,28031,21001} When administered intravenously, losartan carboxylic acid is more potent and has a longer duration of action than losartan.{21001} However, the metabolite has very low oral bioavailability.{21001} Losartan, but not its metabolite, inhibits platelet aggregation in vitro.{20999}
Brand:CaymanSKU:- Losartan carboxylic acid is a physiologically active metabolite of losartan, produced by cytochrome P450 isoforms in the liver.{28030} Like the parent compound, losartan carboxylic acid is a potent AT1 antagonist (Kis = 0.57 and 0.67 nM for rat and human forms, respectively), producing a depressor response and vasodilatation.{28032,28031,21001} When administered intravenously, losartan carboxylic acid is more potent and has a longer duration of action than losartan.{21001} However, the metabolite has very low oral bioavailability.{21001} Losartan, but not its metabolite, inhibits platelet aggregation in vitro.{20999}
Brand:CaymanSKU:-
Losartan-d4 contains four deuterium atoms located on the phenyl group. It is intended for use as an internal standard for the quantification of losartan (potassium salt) (Item No. 10006594) by GC- or LC-MS. Losartan is an antagonist of the angiotensin (AT) II receptor subtype AT1 with a Ki value of 5-20 nM.{12997} It has an attenuating effect on vein graft atherosclerosis in rabbits and effectively reduces arterial blood pressure in rats.{12998,13089} Formulations containing losartan have been used to control hypertension while protecting renal function.{12996}
Brand:CaymanSKU:22567 -Out of stock
Losartan-d4 contains four deuterium atoms located on the phenyl group. It is intended for use as an internal standard for the quantification of losartan (potassium salt) (Item No. 10006594) by GC- or LC-MS. Losartan is an antagonist of the angiotensin (AT) II receptor subtype AT1 with a Ki value of 5-20 nM.{12997} It has an attenuating effect on vein graft atherosclerosis in rabbits and effectively reduces arterial blood pressure in rats.{12998,13089} Formulations containing losartan have been used to control hypertension while protecting renal function.{12996}
Brand:CaymanSKU:22567 -Out of stock
Loteprednol etabonate is a glucocorticoid receptor agonist with an affinity 4.3 times that of dexamethasone (Item No. 11015).{40360} It decreases wound healing time in mice and minimizes scarring of rabbit cornea wounds.{40362,40361} Formulations containing loteprednol etabonate are used in the treatment of inflammatory eye conditions.
Brand:CaymanSKU:23305 - 10 mgAvailable on backorder
Loteprednol etabonate is a glucocorticoid receptor agonist with an affinity 4.3 times that of dexamethasone (Item No. 11015).{40360} It decreases wound healing time in mice and minimizes scarring of rabbit cornea wounds.{40362,40361} Formulations containing loteprednol etabonate are used in the treatment of inflammatory eye conditions.
Brand:CaymanSKU:23305 - 25 mgAvailable on backorder
Loteprednol etabonate is a glucocorticoid receptor agonist with an affinity 4.3 times that of dexamethasone (Item No. 11015).{40360} It decreases wound healing time in mice and minimizes scarring of rabbit cornea wounds.{40362,40361} Formulations containing loteprednol etabonate are used in the treatment of inflammatory eye conditions.
Brand:CaymanSKU:23305 - 5 mgAvailable on backorder
Loteprednol etabonate is a glucocorticoid receptor agonist with an affinity 4.3 times that of dexamethasone (Item No. 11015).{40360} It decreases wound healing time in mice and minimizes scarring of rabbit cornea wounds.{40362,40361} Formulations containing loteprednol etabonate are used in the treatment of inflammatory eye conditions.
Brand:CaymanSKU:23305 - 50 mgAvailable on backorder
Loureirin B is a flavonoid originally isolated from D. cochinchinensis, a major component of the traditional herbal medicine dragon’s blood, and has diverse biological activities.{48437,48438,48439} It inhibits Kv1.3-mediated currents, induces membrane depolarization, and reduces calcium influx in Jurkat T cells.{48437} It also inhibits phytohemagglutinin-induced IL-2 release from these cells. Loureirin B (25 μg/ml) reduces type I collagen and fibronectin protein levels in TGF-β1-stimulated fibroblasts as well as contraction of TGF-β1-stimulated fibroblasts in a gel contraction assay.{48438} It reduces type I collagen and fibronectin protein levels and inhibits phosphorylation of ERK and JNK in isolated human hypertrophic scar tissue. Loureirin B increases glucose absorption and intracellular ATP levels in Ins-1 cells via inhibition of the KATP current and intracellular influx of calcium.{48439}
Brand:CaymanSKU:27454 - 10 mgAvailable on backorder
Loureirin B is a flavonoid originally isolated from D. cochinchinensis, a major component of the traditional herbal medicine dragon’s blood, and has diverse biological activities.{48437,48438,48439} It inhibits Kv1.3-mediated currents, induces membrane depolarization, and reduces calcium influx in Jurkat T cells.{48437} It also inhibits phytohemagglutinin-induced IL-2 release from these cells. Loureirin B (25 μg/ml) reduces type I collagen and fibronectin protein levels in TGF-β1-stimulated fibroblasts as well as contraction of TGF-β1-stimulated fibroblasts in a gel contraction assay.{48438} It reduces type I collagen and fibronectin protein levels and inhibits phosphorylation of ERK and JNK in isolated human hypertrophic scar tissue. Loureirin B increases glucose absorption and intracellular ATP levels in Ins-1 cells via inhibition of the KATP current and intracellular influx of calcium.{48439}
Brand:CaymanSKU:27454 - 25 mgAvailable on backorder
Loureirin B is a flavonoid originally isolated from D. cochinchinensis, a major component of the traditional herbal medicine dragon’s blood, and has diverse biological activities.{48437,48438,48439} It inhibits Kv1.3-mediated currents, induces membrane depolarization, and reduces calcium influx in Jurkat T cells.{48437} It also inhibits phytohemagglutinin-induced IL-2 release from these cells. Loureirin B (25 μg/ml) reduces type I collagen and fibronectin protein levels in TGF-β1-stimulated fibroblasts as well as contraction of TGF-β1-stimulated fibroblasts in a gel contraction assay.{48438} It reduces type I collagen and fibronectin protein levels and inhibits phosphorylation of ERK and JNK in isolated human hypertrophic scar tissue. Loureirin B increases glucose absorption and intracellular ATP levels in Ins-1 cells via inhibition of the KATP current and intracellular influx of calcium.{48439}
Brand:CaymanSKU:27454 - 5 mgAvailable on backorder
Loureirin B is a flavonoid originally isolated from D. cochinchinensis, a major component of the traditional herbal medicine dragon’s blood, and has diverse biological activities.{48437,48438,48439} It inhibits Kv1.3-mediated currents, induces membrane depolarization, and reduces calcium influx in Jurkat T cells.{48437} It also inhibits phytohemagglutinin-induced IL-2 release from these cells. Loureirin B (25 μg/ml) reduces type I collagen and fibronectin protein levels in TGF-β1-stimulated fibroblasts as well as contraction of TGF-β1-stimulated fibroblasts in a gel contraction assay.{48438} It reduces type I collagen and fibronectin protein levels and inhibits phosphorylation of ERK and JNK in isolated human hypertrophic scar tissue. Loureirin B increases glucose absorption and intracellular ATP levels in Ins-1 cells via inhibition of the KATP current and intracellular influx of calcium.{48439}
Brand:CaymanSKU:27454 - 50 mgAvailable on backorder
Lovastatin is an HMG-CoA reductase inhibitor that was initially isolated from A. terreus.{15081} It is a prodrug of its more potent metabolite, lovastatin hydroxy acid (Item No. 10010339). Both competitively inhibit HMG-CoA reductase with Ki values of 1.4 and 0.6 nM for lovastatin and the open ring, hydroxy acid form, respectively.{15251} Lovastatin (8 mg/kg/day) reduces plasma cholesterol in dogs by 29% over a three week period. It also suppresses TNF-induced NF-κB activation (IC50 ~ 15 µM), which potentiates apoptosis in human myeloid leukemia cells and thus, may be useful in treating cancer.{15363} Formulations containing lovastatin were the first HMG-CoA reductase inhibitors to be used in the treatment of hypercholesterolemia.
Brand:CaymanSKU:10010338 - 10 mgAvailable on backorder
Lovastatin is an HMG-CoA reductase inhibitor that was initially isolated from A. terreus.{15081} It is a prodrug of its more potent metabolite, lovastatin hydroxy acid (Item No. 10010339). Both competitively inhibit HMG-CoA reductase with Ki values of 1.4 and 0.6 nM for lovastatin and the open ring, hydroxy acid form, respectively.{15251} Lovastatin (8 mg/kg/day) reduces plasma cholesterol in dogs by 29% over a three week period. It also suppresses TNF-induced NF-κB activation (IC50 ~ 15 µM), which potentiates apoptosis in human myeloid leukemia cells and thus, may be useful in treating cancer.{15363} Formulations containing lovastatin were the first HMG-CoA reductase inhibitors to be used in the treatment of hypercholesterolemia.
Brand:CaymanSKU:10010338 - 5 mgAvailable on backorder
Lovastatin is an HMG-CoA reductase inhibitor that was initially isolated from A. terreus.{15081} It is a prodrug of its more potent metabolite, lovastatin hydroxy acid (Item No. 10010339). Both competitively inhibit HMG-CoA reductase with Ki values of 1.4 and 0.6 nM for lovastatin and the open ring, hydroxy acid form, respectively.{15251} Lovastatin (8 mg/kg/day) reduces plasma cholesterol in dogs by 29% over a three week period. It also suppresses TNF-induced NF-κB activation (IC50 ~ 15 µM), which potentiates apoptosis in human myeloid leukemia cells and thus, may be useful in treating cancer.{15363} Formulations containing lovastatin were the first HMG-CoA reductase inhibitors to be used in the treatment of hypercholesterolemia.
Brand:CaymanSKU:10010338 - 50 mgAvailable on backorder
Lovastatin hydroxy acid is a potent and competitive inhibitor of HMG-CoA reductase (Ki = 0.6 nM).{15251} It is the more potent, open ring, hydroxy acid form of its prodrug, lovastatin (Item No. 10010338).{39152}
Brand:CaymanSKU:10010339 - 1 mgAvailable on backorder
Lovastatin hydroxy acid is a potent and competitive inhibitor of HMG-CoA reductase (Ki = 0.6 nM).{15251} It is the more potent, open ring, hydroxy acid form of its prodrug, lovastatin (Item No. 10010338).{39152}
Brand:CaymanSKU:10010339 - 10 mgAvailable on backorder
Lovastatin hydroxy acid is a potent and competitive inhibitor of HMG-CoA reductase (Ki = 0.6 nM).{15251} It is the more potent, open ring, hydroxy acid form of its prodrug, lovastatin (Item No. 10010338).{39152}
Brand:CaymanSKU:10010339 - 25 mgAvailable on backorder
Lovastatin hydroxy acid is a potent and competitive inhibitor of HMG-CoA reductase (Ki = 0.6 nM).{15251} It is the more potent, open ring, hydroxy acid form of its prodrug, lovastatin (Item No. 10010338).{39152}
Brand:CaymanSKU:10010339 - 5 mgAvailable on backorder
Loxapine is an atypical antipsychotic drug that displays high affinity for histamine, 5-HT, dopamine, and α1-adrenergic receptors (Ki values are 7, 7.7, 9.5, 12, and 31 nM for H1, 5-HT2A, 5-HT2C, D2, and α1A, respectively).{24252,24253} It reduces agitation associated with schizophrenia or bipolar disorder.{32724}
Brand:CaymanSKU:20760 -Available on backorder
Loxapine is an atypical antipsychotic drug that displays high affinity for histamine, 5-HT, dopamine, and α1-adrenergic receptors (Ki values are 7, 7.7, 9.5, 12, and 31 nM for H1, 5-HT2A, 5-HT2C, D2, and α1A, respectively).{24252,24253} It reduces agitation associated with schizophrenia or bipolar disorder.{32724}
Brand:CaymanSKU:20760 -Available on backorder
Loxapine is an atypical antipsychotic drug that displays high affinity for histamine, 5-HT, dopamine, and α1-adrenergic receptors (Ki values are 7, 7.7, 9.5, 12, and 31 nM for H1, 5-HT2A, 5-HT2C, D2, and α1A, respectively).{24252,24253} It reduces agitation associated with schizophrenia or bipolar disorder.{32724}
Brand:CaymanSKU:20760 -Available on backorder
Loxiglumide is a cholecystokinin (CCK) receptor antagonist that inhibits CCK-8 binding to central and peripheral CCK receptors with Ki values of 9.1 and 0.33 μM, respectively.{41979} It inhibits CCK-8-induced release of acetylcholine from isolated guinea pig gallbladder (IC50 = 10 nM).{41980} Loxiglumide (50 μM) reduces the invasion of PANC-1 and MiaPaCa-2 human pancreatic cancer cells by 83.1 and 82.9%, respectively, in vitro.{41981} Loxiglumide (10-5,000 μM) reduces DNA synthesis in PC-TI and PC-YY human pancreatic cancer cells in a concentration-dependent manner (IC50s = 160 and 74 μM, respectively).{41982} It reduces the tumor growth rate by 37.5 and 38%, respectively, in PC-TI and PC-YY mouse xenograft models when administered at a dose of 250 mg/kg. Loxiglumide is toxic to mice with LD50 values ranging from 440 to 500 mg/kg dependent on the route of administration. In a rat model of acute pancreatitis, loxiglumide (50 mg/kg, s.c.) reduces serum concentrations of CCK, amylase, and lipase by greater than 60%, as well as tissue hemorrhaging and acinar cell necrosis.{41983}
Brand:CaymanSKU:25534 - 10 mgAvailable on backorder
Loxiglumide is a cholecystokinin (CCK) receptor antagonist that inhibits CCK-8 binding to central and peripheral CCK receptors with Ki values of 9.1 and 0.33 μM, respectively.{41979} It inhibits CCK-8-induced release of acetylcholine from isolated guinea pig gallbladder (IC50 = 10 nM).{41980} Loxiglumide (50 μM) reduces the invasion of PANC-1 and MiaPaCa-2 human pancreatic cancer cells by 83.1 and 82.9%, respectively, in vitro.{41981} Loxiglumide (10-5,000 μM) reduces DNA synthesis in PC-TI and PC-YY human pancreatic cancer cells in a concentration-dependent manner (IC50s = 160 and 74 μM, respectively).{41982} It reduces the tumor growth rate by 37.5 and 38%, respectively, in PC-TI and PC-YY mouse xenograft models when administered at a dose of 250 mg/kg. Loxiglumide is toxic to mice with LD50 values ranging from 440 to 500 mg/kg dependent on the route of administration. In a rat model of acute pancreatitis, loxiglumide (50 mg/kg, s.c.) reduces serum concentrations of CCK, amylase, and lipase by greater than 60%, as well as tissue hemorrhaging and acinar cell necrosis.{41983}
Brand:CaymanSKU:25534 - 25 mgAvailable on backorder
Loxiglumide is a cholecystokinin (CCK) receptor antagonist that inhibits CCK-8 binding to central and peripheral CCK receptors with Ki values of 9.1 and 0.33 μM, respectively.{41979} It inhibits CCK-8-induced release of acetylcholine from isolated guinea pig gallbladder (IC50 = 10 nM).{41980} Loxiglumide (50 μM) reduces the invasion of PANC-1 and MiaPaCa-2 human pancreatic cancer cells by 83.1 and 82.9%, respectively, in vitro.{41981} Loxiglumide (10-5,000 μM) reduces DNA synthesis in PC-TI and PC-YY human pancreatic cancer cells in a concentration-dependent manner (IC50s = 160 and 74 μM, respectively).{41982} It reduces the tumor growth rate by 37.5 and 38%, respectively, in PC-TI and PC-YY mouse xenograft models when administered at a dose of 250 mg/kg. Loxiglumide is toxic to mice with LD50 values ranging from 440 to 500 mg/kg dependent on the route of administration. In a rat model of acute pancreatitis, loxiglumide (50 mg/kg, s.c.) reduces serum concentrations of CCK, amylase, and lipase by greater than 60%, as well as tissue hemorrhaging and acinar cell necrosis.{41983}
Brand:CaymanSKU:25534 - 5 mgAvailable on backorder
Loxiglumide is a cholecystokinin (CCK) receptor antagonist that inhibits CCK-8 binding to central and peripheral CCK receptors with Ki values of 9.1 and 0.33 μM, respectively.{41979} It inhibits CCK-8-induced release of acetylcholine from isolated guinea pig gallbladder (IC50 = 10 nM).{41980} Loxiglumide (50 μM) reduces the invasion of PANC-1 and MiaPaCa-2 human pancreatic cancer cells by 83.1 and 82.9%, respectively, in vitro.{41981} Loxiglumide (10-5,000 μM) reduces DNA synthesis in PC-TI and PC-YY human pancreatic cancer cells in a concentration-dependent manner (IC50s = 160 and 74 μM, respectively).{41982} It reduces the tumor growth rate by 37.5 and 38%, respectively, in PC-TI and PC-YY mouse xenograft models when administered at a dose of 250 mg/kg. Loxiglumide is toxic to mice with LD50 values ranging from 440 to 500 mg/kg dependent on the route of administration. In a rat model of acute pancreatitis, loxiglumide (50 mg/kg, s.c.) reduces serum concentrations of CCK, amylase, and lipase by greater than 60%, as well as tissue hemorrhaging and acinar cell necrosis.{41983}
Brand:CaymanSKU:25534 - 50 mgAvailable on backorder
LOXO-101 is an inhibitor of the tropomyosin-related kinases TrkA, TrkB, and TrkC (IC50s = 2-20 nM).{42680} It is selective for TrkA, -B, and -C over a panel of 226 kinases at 1 μM. LOXO-101 inhibits the growth of CUTO-3.29, KM12, and MO-91 patient-derived cancer cell lines (IC50s = In vivo, LOXO-101 (60 and 200 mg/kg) reduces tumor growth in a KM12 mouse xenograft model.
Brand:CaymanSKU:27056 - 1 mgAvailable on backorder
LOXO-101 is an inhibitor of the tropomyosin-related kinases TrkA, TrkB, and TrkC (IC50s = 2-20 nM).{42680} It is selective for TrkA, -B, and -C over a panel of 226 kinases at 1 μM. LOXO-101 inhibits the growth of CUTO-3.29, KM12, and MO-91 patient-derived cancer cell lines (IC50s = In vivo, LOXO-101 (60 and 200 mg/kg) reduces tumor growth in a KM12 mouse xenograft model.
Brand:CaymanSKU:27056 - 10 mgAvailable on backorder
LOXO-101 is an inhibitor of the tropomyosin-related kinases TrkA, TrkB, and TrkC (IC50s = 2-20 nM).{42680} It is selective for TrkA, -B, and -C over a panel of 226 kinases at 1 μM. LOXO-101 inhibits the growth of CUTO-3.29, KM12, and MO-91 patient-derived cancer cell lines (IC50s = In vivo, LOXO-101 (60 and 200 mg/kg) reduces tumor growth in a KM12 mouse xenograft model.
Brand:CaymanSKU:27056 - 25 mgAvailable on backorder
LOXO-101 is an inhibitor of the tropomyosin-related kinases TrkA, TrkB, and TrkC (IC50s = 2-20 nM).{42680} It is selective for TrkA, -B, and -C over a panel of 226 kinases at 1 μM. LOXO-101 inhibits the growth of CUTO-3.29, KM12, and MO-91 patient-derived cancer cell lines (IC50s = In vivo, LOXO-101 (60 and 200 mg/kg) reduces tumor growth in a KM12 mouse xenograft model.
Brand:CaymanSKU:27056 - 5 mgAvailable on backorder
LOXO-195 is an inhibitor of the receptor tyrosine kinases TrkA and TrkC (IC50s = 0.6 and G595R, TrkAG667C, TrkCG623R, and TrkCG696A (IC50s = 2, 9.8, 2.3, and 50 value of 1.9 nM. It selectively inhibits proliferation of Trk fusion-positive K12, CUTO-3, and MO-91 cell lines (IC50s = ≤5 nM) over Trk fusion-negative cell lines when used at concentrations up to 10 μM. LOXO-195 (≥30 mg/kg) reduces tumor growth in TrkA-dependent KM12, as well as NIH 3T3 ΔTrkA, ΔTrkA + TrkAG595R, and ΔTrkA + TrkAG667C mouse xenograft models.
Brand:CaymanSKU:27062 - 1 mgAvailable on backorder
LOXO-195 is an inhibitor of the receptor tyrosine kinases TrkA and TrkC (IC50s = 0.6 and G595R, TrkAG667C, TrkCG623R, and TrkCG696A (IC50s = 2, 9.8, 2.3, and 50 value of 1.9 nM. It selectively inhibits proliferation of Trk fusion-positive K12, CUTO-3, and MO-91 cell lines (IC50s = ≤5 nM) over Trk fusion-negative cell lines when used at concentrations up to 10 μM. LOXO-195 (≥30 mg/kg) reduces tumor growth in TrkA-dependent KM12, as well as NIH 3T3 ΔTrkA, ΔTrkA + TrkAG595R, and ΔTrkA + TrkAG667C mouse xenograft models.
Brand:CaymanSKU:27062 - 10 mgAvailable on backorder
LOXO-195 is an inhibitor of the receptor tyrosine kinases TrkA and TrkC (IC50s = 0.6 and G595R, TrkAG667C, TrkCG623R, and TrkCG696A (IC50s = 2, 9.8, 2.3, and 50 value of 1.9 nM. It selectively inhibits proliferation of Trk fusion-positive K12, CUTO-3, and MO-91 cell lines (IC50s = ≤5 nM) over Trk fusion-negative cell lines when used at concentrations up to 10 μM. LOXO-195 (≥30 mg/kg) reduces tumor growth in TrkA-dependent KM12, as well as NIH 3T3 ΔTrkA, ΔTrkA + TrkAG595R, and ΔTrkA + TrkAG667C mouse xenograft models.
Brand:CaymanSKU:27062 - 5 mgAvailable on backorder
Loxoribine is a guanosine derivative and an agonist of toll-like receptor 7 (TLR7).{42514,42515} It is selective for TLR7 over other human TLRs in a cell-based reporter assay at 1 mM.{42515}. Loxoribine induces proliferation, increases the antibody response to sheep red blood cells, and activates natural killer cell activity against Yac-1 lymphoma cells in murine splenocyte cultures (EC50s = 10-50, 3-20, and 13-22 μM, respectively).{42514} Loxoribine (250 μM) increases production of IL-12, IL-23, IL-27, and IL-10 by human monocyte-derived dendritic cells (MoDCs).{42516} Loxoribine-treated MoDCs induce higher levels of IL-17 and IFN-γ secretion by co-cultured allogeneic CD4+ T cells compared to control MoDCs. Loxoribine (120 mg/kg) reduces the number of pulmonary metastases in the B16 mouse model of melanoma, an effect enhanced by co-administration of IL-2, and exhibits adjuvant activity in mice immunized with a B16 tumor vaccine.{42517}
Brand:CaymanSKU:21186 -Out of stock
Loxoribine is a guanosine derivative and an agonist of toll-like receptor 7 (TLR7).{42514,42515} It is selective for TLR7 over other human TLRs in a cell-based reporter assay at 1 mM.{42515}. Loxoribine induces proliferation, increases the antibody response to sheep red blood cells, and activates natural killer cell activity against Yac-1 lymphoma cells in murine splenocyte cultures (EC50s = 10-50, 3-20, and 13-22 μM, respectively).{42514} Loxoribine (250 μM) increases production of IL-12, IL-23, IL-27, and IL-10 by human monocyte-derived dendritic cells (MoDCs).{42516} Loxoribine-treated MoDCs induce higher levels of IL-17 and IFN-γ secretion by co-cultured allogeneic CD4+ T cells compared to control MoDCs. Loxoribine (120 mg/kg) reduces the number of pulmonary metastases in the B16 mouse model of melanoma, an effect enhanced by co-administration of IL-2, and exhibits adjuvant activity in mice immunized with a B16 tumor vaccine.{42517}
Brand:CaymanSKU:21186 -Out of stock
Loxoribine is a guanosine derivative and an agonist of toll-like receptor 7 (TLR7).{42514,42515} It is selective for TLR7 over other human TLRs in a cell-based reporter assay at 1 mM.{42515}. Loxoribine induces proliferation, increases the antibody response to sheep red blood cells, and activates natural killer cell activity against Yac-1 lymphoma cells in murine splenocyte cultures (EC50s = 10-50, 3-20, and 13-22 μM, respectively).{42514} Loxoribine (250 μM) increases production of IL-12, IL-23, IL-27, and IL-10 by human monocyte-derived dendritic cells (MoDCs).{42516} Loxoribine-treated MoDCs induce higher levels of IL-17 and IFN-γ secretion by co-cultured allogeneic CD4+ T cells compared to control MoDCs. Loxoribine (120 mg/kg) reduces the number of pulmonary metastases in the B16 mouse model of melanoma, an effect enhanced by co-administration of IL-2, and exhibits adjuvant activity in mice immunized with a B16 tumor vaccine.{42517}
Brand:CaymanSKU:21186 -Out of stock
Loxoribine is a guanosine derivative and an agonist of toll-like receptor 7 (TLR7).{42514,42515} It is selective for TLR7 over other human TLRs in a cell-based reporter assay at 1 mM.{42515}. Loxoribine induces proliferation, increases the antibody response to sheep red blood cells, and activates natural killer cell activity against Yac-1 lymphoma cells in murine splenocyte cultures (EC50s = 10-50, 3-20, and 13-22 μM, respectively).{42514} Loxoribine (250 μM) increases production of IL-12, IL-23, IL-27, and IL-10 by human monocyte-derived dendritic cells (MoDCs).{42516} Loxoribine-treated MoDCs induce higher levels of IL-17 and IFN-γ secretion by co-cultured allogeneic CD4+ T cells compared to control MoDCs. Loxoribine (120 mg/kg) reduces the number of pulmonary metastases in the B16 mouse model of melanoma, an effect enhanced by co-administration of IL-2, and exhibits adjuvant activity in mice immunized with a B16 tumor vaccine.{42517}
Brand:CaymanSKU:21186 -Out of stock
LP-211 is an agonist of the serotonin (5-HT) receptor subtype 5-HT7 (Ki = 0.58 nM).{48788} It is selective for 5-HT7 over 5-HT1A and dopamine D2 receptors (Kis = 188 and 142 nM, respectively). It induces relaxation of isolated guinea pig ileum precontracted by substance P (Item No. 24035; EC50 = 0.6 μM). LP-211 (100 nM) stimulates neurite outgrowth in primary murine striatal and cortical neurons.{48789}
Brand:CaymanSKU:29659 - 10 mgAvailable on backorder
LP-211 is an agonist of the serotonin (5-HT) receptor subtype 5-HT7 (Ki = 0.58 nM).{48788} It is selective for 5-HT7 over 5-HT1A and dopamine D2 receptors (Kis = 188 and 142 nM, respectively). It induces relaxation of isolated guinea pig ileum precontracted by substance P (Item No. 24035; EC50 = 0.6 μM). LP-211 (100 nM) stimulates neurite outgrowth in primary murine striatal and cortical neurons.{48789}
Brand:CaymanSKU:29659 - 25 mgAvailable on backorder
LP-211 is an agonist of the serotonin (5-HT) receptor subtype 5-HT7 (Ki = 0.58 nM).{48788} It is selective for 5-HT7 over 5-HT1A and dopamine D2 receptors (Kis = 188 and 142 nM, respectively). It induces relaxation of isolated guinea pig ileum precontracted by substance P (Item No. 24035; EC50 = 0.6 μM). LP-211 (100 nM) stimulates neurite outgrowth in primary murine striatal and cortical neurons.{48789}
Brand:CaymanSKU:29659 - 5 mgAvailable on backorder